HOME >> MEDICINE >> NEWS
First US tuberculosis vaccine trial in 60 years begins

A new vaccine, made with several proteins from the bacterium that causes tuberculosis (TB), will soon enter the first phase of human safety testing. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has supported research on the candidate vaccine from its earliest stages. The trial will be conducted in the United States by Seattle biotechnology company Corixa and GlaxoSmithKline Biologicals, a vaccine manufacturer headquartered in Belgium.

"This is the first recombinant tuberculosis vaccine to reach human trials in the United States," says NIAID Director Anthony S. Fauci, M.D. "Indeed, this is the first new TB vaccine to be tested in our country in more than 60 years. This candidate vaccine, as well as other novel products emerging from the TB research and development pipeline, offers hope for reducing the burden of a disease that claims approximately two million lives each year."

The vaccine combines two TB proteins known to stimulate strong immune responses in humans. The proteins were initially identified by screening blood taken from volunteers who never became ill with tuberculosis despite long-term infection with Mycobacterium tuberculosis bacteria. Using recombinant DNA technology, the TB proteins were fused and then combined with adjuvants, substances that further boost the immune system's response to the vaccine. NIAID grants awarded in the late 1990s supported research that uncovered the most effective adjuvant-protein combination.

NIAID's TB program officer, Christine Sizemore, Ph.D., notes, "This clinical trial is a wonderful example of advances made possible through sustained support and creative use of resources in NIAID's TB program." NIAID initially funded Corixa scientists, under the direction of Steven Reed, Ph.D., in their identification of the most promising TB proteins for use in a vaccine. Versions of the candidate vaccine were tested in animals through an NIAID
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
26-Jan-2004


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First tuberculosis vaccine trial years begins

(Date:3/29/2015)... IL (PRWEB) March 29, 2015 The ... Foundation for Women’s Cancer announce today that Dr. ... recipient of the Claudia Cohen Research Foundation Prize for ... at the Society of Gynecologic Oncology 46th Annual Meeting ... Director of the Cedars-Sinai Women’s Cancer Program at the ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 Final ... new transition from Pixel Film Studios, entitled TranSports. ... made exclusively for Final Cut Pro X,” said Christiana ... users the tools needed to effortlessly transition using this ... TranSports, a new and uniquely styled transition pack for ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Could genetic ... a new study by researchers at the ... Produced with the support of the Coffee and Caffeine ... Molecular Psychiatry this past fall, the study—one of several ... of genomic data from more than 120,000 regular coffee ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs has ... on UniWigs during the Easter Holidays from today until ... on April Fools’ Day. , As the winter fades ... corner. Easter Festival, with religious origins to countries in ... after Christmas. The best wig provider, UniWigs, would like ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... correlate with a history of shoulder and elbow injuries, according ... for Sports Medicine’s ( AOSSM ) Specialty Day. , “Our ... associated with a 20% increase in likelihood of a history ... is associated with a 12% increase likelihood of a history ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2
(Date:3/27/2015)... - Russell Williams , President of ... 2015-2016 Quebec Budget, noting the fiscal discipline and the ... However, the association is concerned about the decline of ... intent to strive for a balanced budget this year, ... Quebec,s economic development is encouraging," said Mr. ...
(Date:3/27/2015)... March 27, 2015  Victoria Vein & Surgery Clinic is ... Astanza Duality laser in Victoria, Texas . ... well as advanced laser treatments for a variety of medical ... industry to provide more services for their patients. Since adding ... Victoria residents get rid of their ...
(Date:3/27/2015)... -- A new report from Kalorama Information says that other ... Chile , Colombia and ... firms.  The healthcare research firm said that while ... Latin American continent with a population of over 200 million ... the country,s regional economic clout does not necessarily ensure its ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
Cached News: